https://openbell.ai/ 2026-10-05T11:54:54.704Z hourly 1.0 https://openbell.ai/support 2026-10-05T11:54:54.704Z monthly 0.7 https://openbell.ai/privacy 2026-10-05T11:54:54.704Z monthly 0.5 https://openbell.ai/terms 2026-10-05T11:54:54.704Z monthly 0.5 https://openbell.ai/feed.json 2026-10-05T11:54:54.704Z hourly 0.8 https://openbell.ai/news/SRPT:1791201290988 2026-10-05T11:54:50.988Z daily 0.9 https://cdn.brandfetch.io/SRPT/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a 'Sell' rating on Sarepta Therapeutics (NASDAQ: SRPT) and maintained a price target of $5 for the stock. https://openbell.ai/news/STZ:1791201212335 2026-10-05T11:53:32.335Z daily 0.9 https://cdn.brandfetch.io/STZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud How To Earn $500 A Month From Constellation Brands Stock Ahead Of Q2 Earnings Constellation Brands, Inc. (NYSE: STZ) is set to release its second-quarter earnings on October 6, with analysts expecting earnings of $3.56 per share and quarterly revenue of $2.54 billion, a slight increase from $2.48 billion last year. The company currently offers a quarterly dividend of $1.03 per share, translating to an annual yield of 3.65%. To earn $500 monthly from dividends, an investor would need to hold approximately 1,456 shares, valued at about $164,339. Recently, Constellation Brands shares closed at $112.87, reflecting a 0.1% decrease. https://openbell.ai/news/HURA:1791200972285 2026-10-05T11:49:32.285Z daily 0.9 https://cdn.brandfetch.io/HURA/w/400/h/400?c=1idopYfmtR7ZKg8QMud TuHURA Biosciences Receives U.S. Patent For Administration Of DOR Antagonists TuHURA Biosciences, Inc. (NASDAQ: HURA) has been granted U.S. Patent No. 12,734,168 for its novel therapeutic approach involving Delta Opioid Receptor (DOR) antagonists aimed at enhancing cancer immunotherapy. The patent covers the administration of DOR antagonists to patients with cancers associated with DOR-expressing Myeloid Derived Suppressor Cells (MDSCs) and includes various combination therapies for treating and preventing cancer and metastasis. https://openbell.ai/news/HURA:1791200928714 2026-10-05T11:48:48.714Z daily 0.9 https://cdn.brandfetch.io/HURA/w/400/h/400?c=1idopYfmtR7ZKg8QMud TuHURA Biosciences Receives U.S. Patent For Administration Of DOR Antagonists TuHURA Biosciences, Inc. (NASDAQ: HURA) has been granted U.S. Patent No. 12,734,168 for its novel approach to administering Delta Opioid Receptor (DOR) antagonists in cancer treatment. The patent covers methods to reprogram immunosuppressive environments in patients with cancer associated with DOR-expressing Myeloid Derived Suppressor Cells (MDSCs) and includes various combination therapies aimed at treating and preventing cancer and metastasis. https://openbell.ai/news/CBRS:1791200825734 2026-10-05T11:47:05.734Z daily 0.9 https://cdn.brandfetch.io/CBRS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cerebras Systems shares are trading higher after OpenAI CEO Sam Altman posted on social media saying,"Cerebras is a close partner" openbell Financial News https://openbell.ai/news/UPST:1791200822847 2026-10-05T11:47:02.847Z daily 0.9 https://cdn.brandfetch.io/UPST/w/400/h/400?c=1idopYfmtR7ZKg8QMud Upstart Holdings September 2026 Origination Volume Hits $1.38B, Averaging $53.1M Per Day Across 25.95 Origination Days, Q3 Origination Volume Hits $4.12B, Averaging $51.6M Per Day Across 79.85 Origination Days Upstart Holdings, Inc. reported a monthly origination volume of $1.38 billion for September 2026, averaging $53.1 million per day over 25.95 origination days. For the third quarter of 2026, the total origination volume reached $4.12 billion, with an average of $51.6 million per day across 79.85 origination days. https://openbell.ai/news/GLUE:1791200782831 2026-10-05T11:46:22.831Z daily 0.9 https://cdn.brandfetch.io/GLUE/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a Buy rating on Monte Rosa Therapeutics (NASDAQ: GLUE) and maintained a price target of $25 for the stock. https://openbell.ai/news/PTC:1791200412819 2026-10-05T11:40:12.819Z daily 0.9 https://cdn.brandfetch.io/PTC/w/400/h/400?c=1idopYfmtR7ZKg8QMud PTC shares are trading higher after the company announced it will be acquired by Schneider Electric. openbell Financial News https://openbell.ai/news/GEHC:1791200267325 2026-10-05T11:37:47.325Z daily 0.9 https://cdn.brandfetch.io/GEHC/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'GE HealthCare to Buy Sofie for Nearly $1 Billion to Grow Medical-Imaging Business' - WSJ Exclusive GE HealthCare has announced its intention to acquire Sofie, a medical imaging company, for nearly $1 billion. This strategic move aims to enhance GE HealthCare's capabilities in the medical imaging sector. The acquisition is expected to bolster GE HealthCare's position in the market as it seeks to expand its offerings and drive growth. https://openbell.ai/news/PLRZ:1791200067176 2026-10-05T11:34:27.176Z daily 0.9 https://cdn.brandfetch.io/PLRZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Polyrizon Files New US Divisional Patent Application With USPTO, Further Expanding Its IP Portfolio Relating To Proprietary Mucoadhesive Technology Polyrizon Ltd. has filed a new U.S. divisional patent application with the USPTO, expanding its intellectual property portfolio related to its proprietary mucoadhesive technology for nasal drug delivery. The application, titled 'Mucoadhesive Polymers for Nasal Drug Delivery' (U.S. Patent Application No. 19/823,285), aims to enhance the company's existing patent family and supports various applications for delivering therapeutic agents through mucosal tissues. This move allows Polyrizon to seek additional patent protection for specific aspects of its technology. https://openbell.ai/news/ICE:1791200014163 2026-10-05T11:33:34.163Z daily 0.9 https://cdn.brandfetch.io/ICE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Intercontinental Exchange Launches New Tanker And Container Freight Futures And Options Intercontinental Exchange (ICE) has launched new tanker freight futures for the TD34 and TD15 routes, as well as two cash-settled container freight average price options for Asia to North Europe and Asia to U.S. West Coast. This launch comes amid a 33% increase in average daily volume across ICE's freight markets year-to-date. The new contracts expand ICE's freight complex to over 90 contracts across more than 30 global routes, providing additional tools for customers to manage freight rate risk and volatility in supply chains. https://openbell.ai/news/BBIO:1791199943701 2026-10-05T11:32:23.701Z daily 0.9 https://cdn.brandfetch.io/BBIO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bridgebio Presents New Exploratory Cardiac Data From 12-Month Interim Analysis Of FORTIFY, Phase 3 Clinical Trial Of Oral BBP-418 In Individuals With Limb-Girdle Muscular Dystrophy Type 2I/R9, At 31st Annual Congress Of The World Muscle Society In Hiroshima BridgeBio Pharma, Inc. presented new exploratory cardiac data from the 12-month interim analysis of its Phase 3 clinical trial, FORTIFY, for oral BBP-418 in individuals with limb-girdle muscular dystrophy type 2I/R9. The trial showed that 100% of treated individuals with elevated HS troponin I returned to normal levels by Month 12, compared to 40% in the placebo group (p=0.0248). Additionally, 54% of BBP-418-treated individuals had stable or improved left ventricular ejection fraction (LVEF) at Month 12 versus 25% in the placebo arm (p=0.0262). BBP-418 is currently under FDA Priority Review with a target action date of November 27, 2026. https://openbell.ai/news/CBIO:1791199887525 2026-10-05T11:31:27.525Z daily 0.9 https://cdn.brandfetch.io/CBIO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Crescent Biopharma Receives FDA Clearance For Its Investigational New Drug Application For CR-002 To Treat Advanced Solid Tumors Crescent Biopharma, Inc. (NASDAQ: CBIO) has received FDA clearance for its Investigational New Drug application for CR-002, an antibody drug-conjugate targeting PD-L1, aimed at treating advanced solid tumors. This development marks a significant step in the company's efforts to advance cancer therapies. https://openbell.ai/news/TSM:1791199784395 2026-10-05T11:29:44.395Z daily 0.9 https://cdn.brandfetch.io/TSM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Reported October 3, Elon Must Confirms Chip Production Startup Teralab Is In Discussions With Taiwan Semiconductor Elon Musk has confirmed that Teralab, a chip production startup, is in discussions with Taiwan Semiconductor Manufacturing Company (TSMC). This potential collaboration could impact the semiconductor market, although specific details regarding the nature of the discussions or any financial implications have not been disclosed. The news is significant given TSMC's position as a leading chip manufacturer. https://openbell.ai/news/BNY:1791199565893 2026-10-05T11:26:05.893Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/05/Analyst-Works-On-Personal-Computer-Showi.jpg?width=250&height=187 Bank Of New York Mellon Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Bank of New York Mellon Corporation (NYSE: BNY) is set to report its Q3 earnings on October 15, with analysts predicting earnings of $2.27 per share, an increase from $1.91 per share in the previous year. The expected quarterly revenue is $5.56 billion, up from $5.08 billion last year. The company's shares rose 1% to close at $145.40 on Friday, and several analysts have revised their price targets, with JP Morgan increasing its target from $159 to $161. https://openbell.ai/news/CRVO:1791199541373 2026-10-05T11:25:41.373Z daily 0.9 https://cdn.brandfetch.io/CRVO/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on CervoMed (NASDAQ: CRVO) and maintained a price target of $25 for the company's stock. https://openbell.ai/news/AX:1791199367894 2026-10-05T11:22:47.894Z daily 0.9 https://cdn.brandfetch.io/AX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on Axos Financial, Maintains $128 Price Target Needham analyst Kyle Peterson has reiterated a Buy rating on Axos Financial (NYSE: AX) and maintained a price target of $128 for the stock. This endorsement reflects confidence in the company's performance and potential for growth. https://openbell.ai/news/SMTC:1791199322901 2026-10-05T11:22:02.901Z daily 0.9 https://cdn.brandfetch.io/SMTC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stifel Maintains Buy on Semtech, Raises Price Target to $220 Stifel analyst Tore Svanberg has maintained a 'Buy' rating on Semtech (NASDAQ: SMTC) and increased the price target from $188 to $220. This adjustment reflects a positive outlook for the company's performance in the market. https://openbell.ai/news/JZXN:1791199292979 2026-10-05T11:21:32.979Z daily 0.9 https://cdn.brandfetch.io/JZXN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jiuzi Announces Its AI Smart Imaging And Data Platform Is Accelerating; Maintains Profit Contribution Guidance ~$1.55M Jiuzi Holdings, Inc. (NASDAQ: JZXN) has announced that its AI smart imaging and data platform is evolving into a scalable enterprise-grade solution, with a profit contribution guidance of approximately $1.55 million. The platform aims to enhance operational efficiency across various industries, including smart retail and intelligent security, by integrating advanced data processing capabilities. The global AI image recognition market is projected to grow significantly, supporting Jiuzi's commercialization efforts and aligning with industry trends toward large-scale deployment of smart imaging systems. https://openbell.ai/news/GEO:1791199033872 2026-10-05T11:17:13.872Z daily 0.9 https://cdn.brandfetch.io/GEO/w/400/h/400?c=1idopYfmtR7ZKg8QMud GEO Group Completes Sales Of Its Adelanto West ICE Processing Center, Adelanto East ICE Processing Center, And Desert View Annex To The U.S. And Its Assigns, By And Through DHS, For Gross Price $950M ~$705M In Net Proceeds; Increases Share Buyback Authorization To $1.25B Through 2029 GEO Group has completed the sale of its Adelanto West, Adelanto East, and Desert View ICE Processing Centers to the U.S. government for a gross price of $950 million, expecting net proceeds of approximately $705 million after taxes and fees. The company plans to use these proceeds to reduce debt, repurchase shares, and for general corporate purposes, increasing its share buyback authorization to $1.25 billion through 2029. GEO will continue to provide support services under its existing contract with ICE for these facilities until December 2034. https://openbell.ai/news/ATHE:1791198964199 2026-10-05T11:16:04.199Z daily 0.9 https://cdn.brandfetch.io/ATHE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Alterity Therapeutics Says ATH434 50 mg Slowed Multiple System Atrophy Decline By About 52% In Post Hoc Phase 2 Analysis openbell Financial News https://openbell.ai/news/PCOR:1791198882609 2026-10-05T11:14:42.609Z daily 0.9 https://cdn.brandfetch.io/PCOR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Reiterates Overweight on Procore Technologies, Maintains $65 Price Target Cantor Fitzgerald analyst Mason Marion has reiterated an Overweight rating on Procore Technologies (NYSE: PCOR) and maintained a price target of $65 for the stock. This endorsement reflects confidence in the company's performance and potential for growth. https://openbell.ai/news/MMED:1791198851142 2026-10-05T11:14:11.142Z daily 0.9 https://cdn.brandfetch.io/MMED/w/400/h/400?c=1idopYfmtR7ZKg8QMud MiniMed Study Links More Alert Responses To Better Diabetes Control MiniMed (NASDAQ: MMED) presented new clinical evidence indicating that users of its Smart MDI system who responded to more alerts achieved an average of 8.1 percentage points more Time in Range (TIR) and 0.6 percentage points lower HbA1c over a six-month trial involving 143 participants with type 1 diabetes. The study highlights the importance of timely alerts in managing diabetes through multiple daily injections, which can significantly improve glucose outcomes. The Smart MDI system integrates a smart insulin pen with a continuous glucose monitor via the MiniMed Go app, streamlining diabetes management. https://openbell.ai/news/LITE:1791198807469 2026-10-05T11:13:27.469Z daily 0.9 https://cdn.brandfetch.io/LITE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stifel Maintains Buy on Lumentum Holdings, Raises Price Target to $1232 Stifel analyst Ruben Roy has maintained a Buy rating on Lumentum Holdings (NASDAQ: LITE) and increased the price target from $1100 to $1232. This adjustment reflects a positive outlook for the company. https://openbell.ai/news/TRBG:1791198804391 2026-10-05T11:13:24.391Z daily 0.9 https://cdn.brandfetch.io/TRBG/w/400/h/400?c=1idopYfmtR7ZKg8QMud TurboGen Announces Five-Year Agreement With Undisclosed EU-Based Manufacturer For Development And Production Of Microturbine Systems openbell Financial News https://openbell.ai/news/GILT:1791198759517 2026-10-05T11:12:39.517Z daily 0.9 https://cdn.brandfetch.io/GILT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Gilat Satellite Networks Enters $28M Agreement With Peru's Pronatel To Upgrade Broadband Connectivity Across The Ica Region Gilat Satellite Networks has entered a $28 million agreement with Peru's Pronatel to upgrade broadband connectivity in the Ica region, with project completion expected by mid-2027 followed by a seven-year operational phase. This initiative will enhance internet speeds by 20 times for 116 public institutions and provide free Wi-Fi in 30 public squares. The upgrade aims to improve access to essential digital services such as education and healthcare, building on Gilat Perú's experience in deploying large-scale telecommunications networks across diverse environments. https://openbell.ai/news/INTT:1791198747960 2026-10-05T11:12:27.960Z daily 0.9 https://cdn.brandfetch.io/INTT/w/400/h/400?c=1idopYfmtR7ZKg8QMud InTest Reports Preliminary Q3 Orders Of $48M-$50M, Up 28%-33%; Revenue At High End Of $33M-$35M Guidance openbell Financial News https://openbell.ai/news/INCY:1791198716548 2026-10-05T11:11:56.548Z daily 0.9 https://cdn.brandfetch.io/INCY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stifel Maintains Buy on Incyte, Raises Price Target to $157 Stifel analyst Stephen Willey has reaffirmed a Buy rating on Incyte (NASDAQ: INCY) and increased the price target from $145 to $157. This adjustment reflects a positive outlook for the company's performance. https://openbell.ai/news/STOK:1791198659958 2026-10-05T11:10:59.958Z daily 0.9 https://cdn.brandfetch.io/STOK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stoke Therapeutics Says FDA Willing To Accept Planned Phase 3 Cognition And Behavior Analysis For Zorevunersen In Dravet Syndrome openbell Financial News https://openbell.ai/news/MSLE:1791198649633 2026-10-05T11:10:49.633Z daily 0.9 https://cdn.brandfetch.io/MSLE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform Satellos Bioscience Inc. has been granted U.S. Patent No. 12,747,245 by the United States Patent and Trademark Office, covering its lead drug candidate forazapadin and a broader class of AAK1 inhibitors. This patent provides intellectual property protection until September 6, 2044, with the possibility of a Patent Term Extension following future U.S. marketing approval. The company focuses on developing treatments for degenerative muscle diseases. https://openbell.ai/news/BETA:1791198628169 2026-10-05T11:10:28.169Z daily 0.9 https://cdn.brandfetch.io/BETA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Reiterates Overweight on BETA Technologies, Maintains $31 Price Target Cantor Fitzgerald analyst Andres Sheppard has reiterated an Overweight rating on BETA Technologies (NYSE: BETA) and maintained a price target of $31 for the stock. This endorsement suggests a positive outlook for the company's performance in the market. https://openbell.ai/news/NRIX:1791198620697 2026-10-05T11:10:20.697Z daily 0.9 https://cdn.brandfetch.io/NRIX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Nurix Gets $10M As Gilead Extends Drug Discovery Deal Nurix Therapeutics, Inc. has secured a $10 million research term extension fee from Gilead Sciences as they extend their collaboration on an undisclosed oncology program by two years. This marks the second such extension since their partnership began in 2019, which allows Gilead to license drug candidates developed by Nurix, while Nurix retains a 50/50 profit and loss sharing option on up to two programs in the U.S. Nurix could potentially receive up to $1.3 billion in total payments based on future milestones and is also eligible for tiered royalties on net sales from commercial products. https://openbell.ai/news/CWH:1791198618226 2026-10-05T11:10:18.226Z daily 0.9 https://cdn.brandfetch.io/CWH/w/400/h/400?c=1idopYfmtR7ZKg8QMud Camping World Expects FY26 Adjusted EBITDA To Be Below The Low End Of Its Previously Communicated Guidance Range Of $230M-$270M; Current Outlook Takes Into Account Broad Range Of Potential Outcomes Amid Continued Uncertainty Regarding Macroeconomic Conditions And RV Industry Demand Camping World Holdings, Inc. announced on October 5, 2026, that it expects its full-year 2026 Adjusted EBITDA to be below the previously communicated guidance range of $230 million to $270 million due to ongoing macroeconomic uncertainties and weakened RV industry demand. The company noted a decline in combined new and used vehicle unit sales, leading to a more promotional environment and pressure on vehicle margins. In response, Camping World is accelerating $100 million in SG&A savings initiatives, implementing additional headcount reductions for $50 million in annual savings, and exploring refinancing options for its term loan facility to enhance financial flexibility. https://openbell.ai/news/RZLT:1791198581813 2026-10-05T11:09:41.813Z daily 0.9 https://cdn.brandfetch.io/RZLT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Rezolute Gets FDA Recommendation For Pre-BLA Meeting Ahead Of Ersodetug BLA Submission For Congenital Hyperinsulinism Treatment. Rezolute, Inc. (NASDAQ: RZLT) has received a recommendation from the FDA for a pre-BLA meeting regarding its treatment, ersodetug, for congenital hyperinsulinism (HI). Although the Phase 3 sunRIZE study did not meet its primary endpoint, the FDA acknowledged the challenges in measuring hypoglycemia in this patient population and encouraged Rezolute to proceed with the meeting. The company is also on track to report topline results from its Phase 3 upLIFT study for tumor HI this quarter, which may influence its overall BLA submission strategy. https://openbell.ai/news/AMBQ:1791198545045 2026-10-05T11:09:05.045Z daily 0.9 https://cdn.brandfetch.io/AMBQ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stifel Maintains Buy on Ambiq Micro, Raises Price Target to $85 Stifel analyst Tore Svanberg has maintained a Buy rating on Ambiq Micro (NYSE: AMBQ) and increased the price target from $75 to $85. This adjustment reflects a positive outlook for the company's performance. https://openbell.ai/news/FTHM:1791198489786 2026-10-05T11:08:09.786Z daily 0.9 https://cdn.brandfetch.io/FTHM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Fathom And Neighborhood Intelligence Call Off Merger Over Valuation Concerns Fathom Holdings Inc. (FTHM) and Neighborhood Intelligence, Inc. (NXH) have mutually agreed to terminate their merger agreement due to concerns that current valuations do not reflect the fair value of either company. Following discussions with shareholders, Neighborhood Intelligence decided to retain ownership of its blockchain and digital asset investments, believing this will provide the greatest opportunity for future value. The companies concluded that the timing for a merger is not appropriate at this moment. https://openbell.ai/news/AER:1791198487192 2026-10-05T11:08:07.192Z daily 0.9 https://cdn.brandfetch.io/AER/w/400/h/400?c=1idopYfmtR7ZKg8QMud AerCap Says It Bought Back 5.3M Shares For About $783M In Q3; Signed 85 Lease Agreements, Completed 85 Sale Transactions openbell Financial News https://openbell.ai/news/BKR:1791198459780 2026-10-05T11:07:39.780Z daily 0.9 https://cdn.brandfetch.io/BKR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Baker Hughes Enters Two Strategic Agreements To Accelerate Revitalization Of Venezuela’s Energy Infrastructure Across The Natural Gas Value Chain Baker Hughes has entered into two strategic agreements aimed at revitalizing Venezuela's energy infrastructure, specifically within the natural gas value chain. The first agreement is a strategic alliance with PDVSA, Lindsayca, and Fulcrum LNG, Inc. to enhance natural gas infrastructure, while the second is a Memorandum of Understanding with New Stratus Energy Inc. to develop future oil and gas prospects. These collaborations will leverage Baker Hughes' extensive energy solutions and technologies to unlock Venezuela's natural gas potential and support critical infrastructure development. https://openbell.ai/news/PBM:1791198391094 2026-10-05T11:06:31.094Z daily 0.9 https://cdn.brandfetch.io/PBM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Psyence Biomedical Signs Manufacturing Services Agreement With DEA-Registered Benuvia For Planned U.S. Manufacture Of Pharmaceutical-Grade Ibogaine Active Pharmaceutical Ingredient Psyence Biomedical has signed a manufacturing services agreement with Benuvia, which operates a DEA-registered facility in Texas, to produce pharmaceutical-grade ibogaine. This partnership aims to establish U.S. manufacturing capabilities for ibogaine, aligning with Psyence's strategy to create an integrated supply and regulatory development platform through TIRC. The agreement supports TIRC's exclusive access to PsyLabs' ibogaine as outlined in a previous term sheet. https://openbell.ai/news/MX:1791198376445 2026-10-05T11:06:16.445Z daily 0.9 https://cdn.brandfetch.io/MX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Magnachip Launches 15 New Power Chips For TVs And Computers Magnachip Semiconductor Corporation (NYSE: MX) has launched 15 new sixth-generation E6 super-junction MOSFETs aimed at consumer and computing power applications. The E6 Series includes 500 V and 600 V MOSFETs designed to enhance thermal, switching, and EMI performance, with the 600 V MOSFET operating at approximately 5.3% lower temperature compared to the previous generation. This new product line addresses the growing demand for efficient power management in compact electronic designs. https://openbell.ai/news/AMD:1791198362151 2026-10-05T11:06:02.151Z daily 0.9 https://cdn.brandfetch.io/AMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stifel Maintains Buy on Advanced Micro Devices, Raises Price Target to $700 Stifel analyst Ruben Roy has maintained a 'Buy' rating on Advanced Micro Devices (NASDAQ: AMD) and increased the price target from $635 to $700. This adjustment reflects a positive outlook on the company's performance. https://openbell.ai/news/SMMT:1791198355893 2026-10-05T11:05:55.893Z daily 0.9 https://cdn.brandfetch.io/SMMT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Summit Therapeutics Announces Closing Of AstraZeneca's $2B Convertible Preferred Investment, Equivalent To $18.36/Share Of Common Stock openbell Financial News https://openbell.ai/news/CHRW:1791198287435 2026-10-05T11:04:47.435Z daily 0.9 https://cdn.brandfetch.io/CHRW/w/400/h/400?c=1idopYfmtR7ZKg8QMud C.H. Robinson To Buy RXO In $5.8B Cash-And-Stock Deal C.H. Robinson Worldwide, Inc. has announced a definitive agreement to acquire RXO Inc. for $5.8 billion in a cash-and-stock deal, creating a combined company with an enterprise value exceeding $25 billion. RXO shareholders will receive $17.25 per share in cash and 0.0856 shares of C.H. Robinson stock, representing a 27% premium to RXO's 90-day average price. The merger, expected to close in the first half of 2027, aims to generate approximately $300 million in cost synergies within two years and enhance C.H. Robinson's multi-modal platform. The transaction has been unanimously approved by both companies' boards and is subject to regulatory approval and RXO shareholder consent. https://openbell.ai/news/BRIA:1791198257149 2026-10-05T11:04:17.149Z daily 0.9 https://cdn.brandfetch.io/BRIA/w/400/h/400?c=1idopYfmtR7ZKg8QMud BrilliA Acquires Majority Equity Interest In Neubodi Holdings; Terms Undisclosed BrilliA Incorporated (NYSE: BRIA) has acquired a majority equity interest in Neubodi Holdings Sdn. Bhd., a Malaysian lingerie brand, effective August 1, 2026. This acquisition aims to establish a branded B2C retail platform and is part of BrilliA's strategy to expand its multi-brand intimate apparel portfolio in Southeast Asia, moving beyond its current B2B supply and design operations. The terms of the acquisition have not been disclosed. https://openbell.ai/news/WTFC:1791198233703 2026-10-05T11:03:53.703Z daily 0.9 https://cdn.brandfetch.io/WTFC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Piper Sandler Maintains Overweight on Wintrust Financial, Raises Price Target to $195 Piper Sandler analyst Nathan Race has maintained an Overweight rating on Wintrust Financial (NASDAQ: WTFC) and raised the price target from $186 to $195. This adjustment reflects a positive outlook for the company. https://openbell.ai/news/DV:1791198178414 2026-10-05T11:02:58.414Z daily 0.9 https://cdn.brandfetch.io/DV/w/400/h/400?c=1idopYfmtR7ZKg8QMud DoubleVerify Announces Launch Of Attribution Measurement For Advertising On ChatGPT DoubleVerify (NYSE: DV) has launched attribution measurement for advertising on ChatGPT, allowing advertisers to track the impact of ChatGPT Ads on customer journeys and return on ad spend (ROAS). Additionally, DoubleVerify and OpenAI are collaborating on a brand suitability evaluation pilot to help assess brand suitability policies while maintaining user privacy. https://openbell.ai/news/ALEC:1791198128600 2026-10-05T11:02:08.600Z daily 0.9 https://cdn.brandfetch.io/ALEC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Alector Teams Up With Genentech On Potential Parkinson’s Treatment Alector, Inc. has entered into an exclusive global licensing agreement with Genentech, granting Genentech worldwide rights to develop and commercialize Alector’s AL050 program, aimed at treating GCase deficiency associated with Parkinson’s Disease. AL050 combines an engineered glucocerebrosidase (GCase) with a transport mechanism designed to deliver the enzyme across the blood-brain barrier, potentially reducing neurodegeneration. This collaboration marks a significant strategic partnership for Alector in the biotechnology sector. https://openbell.ai/news/MRSH:1791198065967 2026-10-05T11:01:05.967Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/05/Other-Analysts-Turn-Bullish.jpg?width=250&height=187 Top Wall Street Forecasters Revamp Marsh Expectations Ahead Of Q3 Earnings Marsh & McLennan Companies, Inc. (NYSE: MRSH) is set to release its Q3 earnings report on October 15, with analysts expecting earnings of $1.97 per share and revenue of $6.65 billion, up from $1.85 per share and $6.35 billion in the previous year. The company recently completed its acquisition of Accel Holdings, Inc. Additionally, MRSH shares fell 1% to close at $170.06 on Friday. https://openbell.ai/news/CBRS:1791197900469 2026-10-05T10:58:20.469Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/05/The-Cerebras-logo-displayed-on-a-smartph.jpg?width=250&height=187 CBRS Stock Surges Over 6% in Monday Pre-Market: What's the Sam Altman Connection? Cerebras Systems Inc. (NASDAQ: CBRS) shares increased by 6.56% in pre-market trading following OpenAI CEO Sam Altman's endorsement of the company as a 'close partner' in AI development. Analyst Tom O'Malley from Barclays noted that concerns regarding OpenAI's reliance on Nvidia GPUs were overblown, reaffirming a strong relationship between OpenAI and Cerebras. Additionally, analyst Paul Meeks upgraded Cerebras to 'Buy' with a price target of $209, citing a significant demand for AI hardware that is expected to outpace supply for years. https://openbell.ai/news/MO:1791197826229 2026-10-05T10:57:06.229Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/05/Schiff-Criticizes-Tariff-Dividend-Plan.jpg?width=250&height=187 Wall Street's Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend Yields Three defensive stocks with high dividend yields have been highlighted: Altria Group Inc (NYSE: MO) with a 6.59% yield, Clorox Co (NYSE: CLX) at 6.22%, and General Mills Inc (NYSE: GIS) yielding 7.62%. Analysts have provided mixed ratings, with Altria receiving a price target increase from $63 to $64 by Barclays, while Clorox's target was cut from $100 to $97 by Citigroup. General Mills recently appointed Dana McNabb as CEO and raised its price target from $32 to $33 by TD Cowen.